Quick Answer
Zenas BioPharma, Inc. reported Operating Income of -$383.06 million for fiscal year 2025.
Zenas BioPharma, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$383.06M | -133.7% |
| 2024 | -$163.89M | -341.2% |
| 2023 | -$37.15M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$52.58M | -28.3% | +4.7% |
| June 30, 2025 | -$55.16M | -38.9% | -47.8% |
| March 31, 2025 | -$37.33M | -35.4% | +8.9% |
| September 30, 2024 | -$40.98M | -215.0% | -3.2% |
| June 30, 2024 | -$39.70M | — | -44.0% |
| March 31, 2024 | -$27.58M | — | -177.4% |
| September 30, 2023 | $35.62M | — | — |
- Zenas BioPharma, Inc. showed a decrease of -133.7% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, Zenas BioPharma, Inc.’s operating income has declined by 931.2% (from -$37.15 million to -$383.06 million).
- The most recent figure is from Zenas BioPharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: